J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV...

cafead

Administrator
Staff member
  • cafead   Jul 25, 2023 at 09:32: PM
via To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy. Now, the partners have a clutch of data suggesting their long-acting injectable is popular among patients.

article source
 

<